A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
City of Hope Medical Center
National Institutes of Health Clinical Center (CC)
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Mayo Clinic
Janssen Research & Development, LLC
Gilead Sciences
M.D. Anderson Cancer Center
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Masonic Cancer Center, University of Minnesota
Augusta University
M.D. Anderson Cancer Center
Washington University School of Medicine
University of California, San Francisco
Peking University People's Hospital
Memorial Sloan Kettering Cancer Center
Massachusetts General Hospital
Hackensack Meridian Health
Essen Biotech
Mayo Clinic
Medical College of Wisconsin
University of Alabama at Birmingham
Thomas Jefferson University
Northside Hospital, Inc.
University of Rochester
Caribou Biosciences, Inc.
SWOG Cancer Research Network
Masonic Cancer Center, University of Minnesota
Indapta Therapeutics, INC.
Institute of Hematology & Blood Diseases Hospital, China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Tongji Hospital
The Affiliated People's Hospital of Ningbo University
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
University of Liege
The Affiliated People's Hospital of Ningbo University